Mary Tenuta

Mary Tenuta

Auto-generated profile, based on publicly available information

Mary Tenuta

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2022 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
ANAlessio D. Nahmad
Alessio D. Nahmad
CLCicera R. Lazzarotto
Cicera R. Lazzarotto
NZNatalie Zelikson
Natalie Zelikson
TKTalia Kustin
Talia Kustin
MTMary Tenuta
Mary Tenuta
ABAdi Barzel
Adi Barzel

17 November 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
DHDeli Huang
Deli Huang
JTJenny Tuyet Tran
Jenny Tuyet Tran
AOAlex Olson
Alex Olson
TVThomas Vollbrecht
Thomas Vollbrecht
MTMary Tenuta
Mary Tenuta
JVJames E. Voss
James E. Voss
HIV broadly neutralizing antibodies (bnAbs) can suppress viremia and protect against HIV infection. However, their elicitation is made difficult by low frequencies of appropriate precursor B cell receptors and the complex maturation pathways required to generate bnAbs from these precursors. Antibody genes can be engineered into B cells for expression as both a functional antigen receptor on cell surfaces and as secreted antibody. Here, we show that HIV bnAb-engineered primary mouse B cells can be adoptively transferred and vaccinated in immunocompetent mice resulting in the expansion of durable bnAb memory and long-lived plasma cells. Somatic hypermutation after immunization indicates that engineered cells have the capacity to respond to an evolving pathogen. These results encourage further exploration of engineered B cell vaccines as a strategy for durable elicitation of HIV bnAbs to protect against infection and as a contributor to a functional HIV cure.

7 December 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
DHDeli Huang
Deli Huang
JTJenny Tuyet Tran
Jenny Tuyet Tran
AOAlex Olson
Alex Olson
TVThomas Vollbrecht
Thomas Vollbrecht
MTMary Tenuta
Mary Tenuta
JVJames E. Voss
James E. Voss
A Correction to this paper has been published: https://doi.org/10.1038/s41467-020-20304-y

9 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
ANA. D. Nahmad
A. D. Nahmad
CLC. R. Lazzarotto
C. R. Lazzarotto
NZN. Zelikson
N. Zelikson
TKT. Kustin
T. Kustin
MTM. Tenuta
M. Tenuta
ABA. Barzel
A. Barzel
As a potential single-shot HIV therapy, transplanted engineered B cells allow robust secretion of broadly neutralizing antibodies (bNAbs). However, ex vivo engineering of autologous B cells is expensive and requires specialized facilities, while allogeneic B cell therapy necessitates MHC compatibility. Here, we develop in vivo B cell engineering, by injecting two adeno associated viral vectors, one coding for saCas9 and another coding for a bNAb. Following immunizations, we demonstrate memory retention and bNAb secretion at neutralizing titers. We observed minimal CRISPR/Cas9 off-target cleavage, using unbiased CHANGE-Seq analysis, while on-target cleavage at undesired tissues is reduced by expressing saCas9 from a B cell specific promoter. In vivo B cell engineering is thus a safe, potent and scalable method for expressing desired antibodies against HIV and beyond. One sentence summary: B cells can be engineered in vivo to robustly secrete anti-HIV bNAbs in a safe, durable and scalable manner.

10 April 2026 in Gene Therapy
Verified
Journal Article
Open access
MTMary Tenuta
Mary Tenuta
MBMorgan Bravo
Morgan Bravo
AOAlex Olson
Alex Olson
CSCelia L. Saney
Celia L. Saney
JWJason Weinfurter
Jason Weinfurter
JVJames E. Voss
James E. Voss
HIV broadly neutralizing antibodies (bnAbs) are promising reagents for prevention and therapy of disease; however, their elicitation is constrained by genetic limitations of the human B cell antigen-receptor (BCR) repertoire. Precision genome-editing offers a potential solution by enabling bnAb genes to be programmed into the BCR repertoire as IgH -modified B cells. Such cells can be vaccinated to elicit durable bnAb memory responses in mice; however, extending this success to non-human primates (NHPs) would be a major advance towards clinical translation. Here, we show that ex vivo reprogrammed NHP B cells can survive autologous infusion and respond to immunization, differentiating into antibody-secreting cells (ASCs) that can produce up to 1 µg/ml of a bnAb in serum following vaccination prime. Although durable transgenic memory responses were not generated, vaccination of engineered cells in secondary lymphoid organoid (SLO) cultures recapitulated transient ASC responses in vitro. These findings suggest that NHP-derived SLOs could provide a platform to optimize engineering and vaccination conditions that drive germinal center maturation of IgH -reprogrammed B cells in a clinically relevant NHP model, supporting the development of engineered B-cell vaccines that generate durable bnAb responses as a potential functional cure for HIV.